Merck & Co., Inc. $MRK Stock Holdings Trimmed by Acumen Wealth Advisors LLC

Acumen Wealth Advisors LLC lowered its position in shares of Merck & Co., Inc. (NYSE:MRK) by 25.5% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 27,226 shares of the company’s stock after selling 9,324 shares during the quarter. Merck & Co., Inc. comprises about 0.9% of Acumen Wealth Advisors LLC’s investment portfolio, making the stock its 29th largest position. Acumen Wealth Advisors LLC’s holdings in Merck & Co., Inc. were worth $3,303,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Chesapeake Wealth Management lifted its stake in Merck & Co., Inc. by 0.6% during the fourth quarter. Chesapeake Wealth Management now owns 14,740 shares of the company’s stock worth $1,552,000 after purchasing an additional 87 shares during the last quarter. South Plains Financial Inc. boosted its holdings in Merck & Co., Inc. by 0.6% in the fourth quarter. South Plains Financial Inc. now owns 15,535 shares of the company’s stock worth $1,635,000 after purchasing an additional 89 shares during the period. Syverson Strege & Co increased its stake in Merck & Co., Inc. by 2.2% during the fourth quarter. Syverson Strege & Co now owns 4,142 shares of the company’s stock valued at $436,000 after purchasing an additional 90 shares during the last quarter. Nations Financial Group Inc. IA ADV increased its stake in Merck & Co., Inc. by 0.4% during the first quarter. Nations Financial Group Inc. IA ADV now owns 23,433 shares of the company’s stock valued at $2,819,000 after purchasing an additional 91 shares during the last quarter. Finally, Westside Investment Management Inc. raised its holdings in shares of Merck & Co., Inc. by 3.1% during the fourth quarter. Westside Investment Management Inc. now owns 3,142 shares of the company’s stock worth $331,000 after purchasing an additional 93 shares during the period. Institutional investors own 76.07% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on MRK. Cantor Fitzgerald restated a “neutral” rating and issued a $120.00 price target on shares of Merck & Co., Inc. in a research report on Monday, July 6th. Bank of America increased their price objective on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the stock a “buy” rating in a research note on Tuesday, June 30th. BMO Capital Markets raised their target price on shares of Merck & Co., Inc. from $135.00 to $142.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. UBS Group lifted their target price on Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a research note on Monday, April 13th. Finally, Weiss Ratings lowered Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a report on Friday, May 15th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $133.94.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Gilead announced that Phase 3 data from the investigational once-weekly oral HIV regimen combining islatravir and lenacapavir will be presented at AIDS 2026, with the primary endpoint showing maintained viral suppression in adults who switched therapies. The update highlights progress in a potentially important HIV program and could support long-term growth expectations. Article: Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
• Positive Sentiment: Phanes Therapeutics expanded its clinical trial collaboration with Merck to evaluate spevatamig with KEYTRUDA and chemotherapy in first-line biliary tract cancer. More combination-trial activity around KEYTRUDA reinforces Merck’s oncology franchise and keeps the company involved in additional mid- to long-term growth opportunities. Article: Phanes Therapeutics Announces Expansion of Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate Spevatamig in Combination with KEYTRUDA® (Pembrolizumab) and Chemotherapy for Treatment of Biliary Tract Cancer
• Neutral Sentiment: Analyst-focused coverage repeated the view that Wall Street’s bullish average rating suggests Merck is worth considering, but the article also questioned how reliable consensus broker recommendations are as a signal. This is more of a sentiment check than a new fundamental catalyst. Article: Is It Worth Investing in Merck (MRK) Based on Wall Street’s Bullish Views?
• Neutral Sentiment: Recent media commentary also noted that Merck had declined more than the broader market in the prior session and that one rating was lowered to Hold, but these items do not appear to reflect a major company-specific setback. Instead, they suggest some near-term caution after the recent move. Article: Merck (MRK) Declines More Than Market: Some Information for Investors
• Negative Sentiment: Coverage from Barron’s focused on what comes after Keytruda, underscoring investor concern about Merck’s long-term dependence on its flagship cancer drug and the need for a future standard-of-care franchise. That narrative can weigh on valuation if investors worry about the post-Keytruda pipeline. Article: What Comes After Merck’s Keytruda? The Race for the Next Standard Cancer Treatment.

Merck & Co., Inc. Stock Performance

MRK stock opened at $126.27 on Wednesday. Merck & Co., Inc. has a 1 year low of $76.66 and a 1 year high of $131.74. The stock has a market capitalization of $311.86 billion, a price-to-earnings ratio of 35.57, a PEG ratio of 4.95 and a beta of 0.19. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. The stock’s fifty day moving average is $120.65 and its two-hundred day moving average is $117.29.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, topping the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The business had revenue of $16.29 billion during the quarter, compared to analyst estimates of $15.85 billion. During the same quarter in the prior year, the firm earned $2.22 earnings per share. The company’s quarterly revenue was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, research analysts predict that Merck & Co., Inc. will post 2.74 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, July 8th. Shareholders of record on Monday, June 15th were paid a $0.85 dividend. The ex-dividend date was Monday, June 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.7%. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 95.77%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.